Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01622556 · ClinicalTrials.gov registry record · Phase 2
Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies
A Phase 2 study, sponsored by University of Virginia.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT01622556: Clinical Trial Phase 2 study, sponsored by University of Virginia.
NCT01622556 is a Phase 2 study that was terminated before completion, run by University of Virginia. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01622556, a Phase 2 study, was terminated before completion, sponsored by University of Virginia.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a phase II study to assess the day 180 event free and overall survival after administration of a specified combination of fludarabine, busulfan, Total Body Irradiation (TBI), and thymoglobulin reduced intensity conditioning and 2 unit UCB stem cell transplant in a single institution setting in patients with hematologic malignancies for whom allogeneic transplantation is indicated.
Primary Outcome
Number of subjects surviving with no events at 180 days post transplantation (Day 0).
Interventions
- DRUG Fludarabine
- DRUG Busulfan
- DRUG Thymoglobulin
- RADIATION Total Body Irradiation
- BIOLOGICAL Umbilical Cord Blood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2012-01 |
| Est. Completion | 2017-01 |
| Phase | Phase 2 |
Why NCT01622556 stopped before completion
NCT01622556 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT01622556 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01622556 about?
NCT01622556 is a clinical study titled "Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies". This is a phase II study to assess the day 180 event free and overall survival after administration of a specified combination of fludarabine, busulfan, Total Body Irradiation (TBI), and thymoglobulin reduced intensity conditioning and 2 unit UCB stem cell transplant in a single institution setting ...
What is the current status of trial NCT01622556?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2012-01. Estimated completion is 2017-01.
What interventions are being tested in trial NCT01622556?
The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG), Thymoglobulin (DRUG), Total Body Irradiation (RADIATION), Umbilical Cord Blood (BIOLOGICAL).
Who is sponsoring clinical trial NCT01622556?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01622556's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia